Proud to see that our effort is acknowledged in the very interesting upcoming book: OBO Semantic Engineer Training. The contribution was exemplified as best practice in the “How to be an Open Science Engineer – maximising impact for a better world” chapter. The work was made under the auspice of CIAO project and was part … Read More
Biovista has been selected as one of the top-20 AI Drug Development companies in a recent article in Forbes View the article here: https://www.forbes.com/sites/yiannismouratidis/2018/12/16/the-rising-star-companies-in-ai-drug-development/
Article by Merle Giles, September 19, 2017 A breath of fresh air came from Graham Anthony who spoke about the pursuit of sustainable healthcare through personalized medicine. The Biovista website calls it ‘drug repositioning’ when HPC drives the ability to more effectively and quickly combine patient and general biomedical data to transform medicine. The key … Read More
Article By Michael Fitzhug, Staff Writer BioWorld, Monday, August 14, 2017 Drug repositioning specialist Biovista Inc. has tapped Hewlett Packard Enterprise Co. (HPE) to add greater computing power to Project Prodigy, a personalized medicine platform that leverages artificial intelligence (AI) to help doctors identify novel drugs for hard-to-treat patients. HPE, a spin-off of HP Inc. … Read More
Interview Of Biovista’s President Aris Persidis in Voice Of America by Jessica Berman; Monday, December 10, 2013 Here is an excerpt… “It is a very easy way to explore whether something that is therapeutically beneficial in one area and for one type of patient might be useful for another type of patient,” said Aris … Read More